Fusobacterium nucleatum
Selected indexed studies
- Fusobacterium nucleatum and cancer. (Periodontol 2000, 2022) [PMID:35244982]
- Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. (Nat Rev Microbiol, 2019) [PMID:30546113]
- Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. (Cell Host Microbe, 2023) [PMID:37130518]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fusobacterium nucleatum and cancer. (2022) pubmed
- Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. (2019) pubmed
- Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. (2023) pubmed
- Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. (2023) pubmed
- Fusobacterium nucleatum and oral cancer: a critical review. (2021) pubmed
- Fusobacterium nucleatum: a commensal-turned pathogen. (2015) pubmed
- Fusobacterium nucleatum aggravates rheumatoid arthritis through FadA-containing outer membrane vesicles. (2023) pubmed
- Fusobacterium nucleatum: Unraveling its potential role in gastric carcinogenesis. (2024) pubmed
- Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. (2013) pubmed
- Fusobacterium nucleatum: ecology, pathogenesis and clinical implications. (2026) pubmed